Upon her Degree in Biological Science in 1984 at the University of Rome, Italy, three Fellowships at the National Research Council (CNR) of Italy and postgraduate courses on confocal and electron microscopy, in 1997 Annalucia Serafino got a permanent position as Researcher at the CNR and was nominated Head of the Confocal and Electron Microscopy Facility. In 2002 she was Head of the Unit “Immunocytochemistry and Ultrastructure” at CNR and in 2005 she was nominated Head of the Unit “Molecular target, preclinical model and immunotherapy”. Since 2009 she is Senior Researcher, at the Institute of Translational Pharmacology (CNR) and Head of Laboratory of “Cytomorphometry and molecular analyses in pre-clinical experimentation”. During the last 15 years, she has been involved in the study of mechanisms underlying cancer development and in discovering new diagnostic/therapeutic targets. She has a long standing expertise in the use of in vitro and in vivo preclinical models of cancer, and in particular of colorectal cancer (CRC). Her main research activities focus on a) analysis of expression of novel markers of tumour development and progression, b) study of molecular signalling involved in CRC carcinogenesis, and in particular of the Wnt/β-catenin pathway, c) evaluation of antitumor and immuno-stimulating activity of natural and synthetic molecules, c) role of endogenous retroviruses in melanoma and breast cancer. She trained various PhD students, published more the 100 articles, including SCI journal papers and book chapters, edited/reviewed for many international journals, coordinated/participated in several national projects and is inventor of a patent on therapeutic use of new pharmaceutical preparations containing antitumoral drugs bound to hyaluronic acid for cancer treatment.